264 related articles for article (PubMed ID: 26351067)
1. Expression of the hyaluronan-mediated motility receptor RHAMM in tumor budding cells identifies aggressive colorectal cancers.
Koelzer VH; Huber B; Mele V; Iezzi G; Trippel M; Karamitopoulou E; Zlobec I; Lugli A
Hum Pathol; 2015 Nov; 46(11):1573-81. PubMed ID: 26351067
[TBL] [Abstract][Full Text] [Related]
2. Receptor for hyaluronic acid-mediated motility (RHAMM, CD168) expression is prognostically important in both nodal negative and nodal positive large cell lung cancer.
Augustin F; Fiegl M; Schmid T; Pomme G; Sterlacci W; Tzankov A
J Clin Pathol; 2015 May; 68(5):368-73. PubMed ID: 25731190
[TBL] [Abstract][Full Text] [Related]
3. RHAMM, p21 combined phenotype identifies microsatellite instability-high colorectal cancers with a highly adverse prognosis.
Zlobec I; Baker K; Terracciano LM; Lugli A
Clin Cancer Res; 2008 Jun; 14(12):3798-806. PubMed ID: 18559599
[TBL] [Abstract][Full Text] [Related]
4. Role of RHAMM within the hierarchy of well-established prognostic factors in colorectal cancer.
Zlobec I; Terracciano L; Tornillo L; Günthert U; Vuong T; Jass JR; Lugli A
Gut; 2008 Oct; 57(10):1413-9. PubMed ID: 18436576
[TBL] [Abstract][Full Text] [Related]
5. Heterogeneity analysis of Metastasis Associated in Colon Cancer 1 (MACC1) for survival prognosis of colorectal cancer patients: a retrospective cohort study.
Koelzer VH; Herrmann P; Zlobec I; Karamitopoulou E; Lugli A; Stein U
BMC Cancer; 2015 Mar; 15():160. PubMed ID: 25884643
[TBL] [Abstract][Full Text] [Related]
6. Intratumoral budding as a potential parameter of tumor progression in mismatch repair-proficient and mismatch repair-deficient colorectal cancer patients.
Lugli A; Vlajnic T; Giger O; Karamitopoulou E; Patsouris ES; Peros G; Terracciano LM; Zlobec I
Hum Pathol; 2011 Dec; 42(12):1833-40. PubMed ID: 21664647
[TBL] [Abstract][Full Text] [Related]
7. RHAMM in liver metastases of stage IV colorectal cancer with mismatch-repair proficient status correlates with tumor budding, cytotoxic T-cells and PD-1/PD-L1.
Burren S; Reche K; Blank A; Galvàn JA; Dawson H; Berger MD; Zlobec I; Lugli A
Pathol Res Pract; 2021 Jul; 223():153486. PubMed ID: 34051513
[TBL] [Abstract][Full Text] [Related]
8. Overexpression of the receptor for hyaluronic acid mediated motility is an independent adverse prognostic factor in colorectal cancer.
Lugli A; Zlobec I; Günthert U; Minoo P; Baker K; Tornillo L; Terracciano L; Jass JR
Mod Pathol; 2006 Oct; 19(10):1302-9. PubMed ID: 16763611
[TBL] [Abstract][Full Text] [Related]
9. Node-negative colorectal cancer at high risk of distant metastasis identified by combined analysis of lymph node status, vascular invasion, and Raf-1 kinase inhibitor protein expression.
Zlobec I; Baker K; Minoo P; Jass JR; Terracciano L; Lugli A
Clin Cancer Res; 2008 Jan; 14(1):143-8. PubMed ID: 18172264
[TBL] [Abstract][Full Text] [Related]
10. The Role of CD44 and RHAMM in Endometrial (Endometrioid Type) Cancer: An Immunohistochemical Study.
Klarić M; Haller H; Brnčić Fischer A; Babarović E; Prijić A; Eminović S
Appl Immunohistochem Mol Morphol; 2019 Sep; 27(8):606-612. PubMed ID: 29734248
[TBL] [Abstract][Full Text] [Related]
11. In situ RHAMM protein expression in acute myeloid leukemia blasts suggests poor overall survival.
Tzankov A; Strasser U; Dirnhofer S; Menter T; Arber C; Jotterand M; Rovo A; Tichelli A; Stauder R; Günthert U
Ann Hematol; 2011 Aug; 90(8):901-9. PubMed ID: 21274712
[TBL] [Abstract][Full Text] [Related]
12. Tumor Budding and PDC Grade Are Stage Independent Predictors of Clinical Outcome in Mismatch Repair Deficient Colorectal Cancer.
Ryan É; Khaw YL; Creavin B; Geraghty R; Ryan EJ; Gibbons D; Hanly A; Martin ST; O'Connell PR; Winter DC; Sheahan K
Am J Surg Pathol; 2018 Jan; 42(1):60-68. PubMed ID: 29112018
[TBL] [Abstract][Full Text] [Related]
13. Epithelial-mesenchymal transition (EMT) protein expression in a cohort of stage II colorectal cancer patients with characterized tumor budding and mismatch repair protein status.
Kevans D; Wang LM; Sheahan K; Hyland J; O'Donoghue D; Mulcahy H; O'Sullivan J
Int J Surg Pathol; 2011 Dec; 19(6):751-60. PubMed ID: 21791486
[TBL] [Abstract][Full Text] [Related]
14. Loss of H2Bub1 Expression is Linked to Poor Prognosis in Nodal Negative Colorectal Cancers.
Melling N; Grimm N; Simon R; Stahl P; Bokemeyer C; Terracciano L; Sauter G; Izbicki JR; Marx AH
Pathol Oncol Res; 2016 Jan; 22(1):95-102. PubMed ID: 26347467
[TBL] [Abstract][Full Text] [Related]
15. Decreased expression of sestrin 2 predicts unfavorable outcome in colorectal cancer.
Wei JL; Fu ZX; Fang M; Guo JB; Zhao QN; Lu WD; Zhou QY
Oncol Rep; 2015 Mar; 33(3):1349-57. PubMed ID: 25572852
[TBL] [Abstract][Full Text] [Related]
16. Active immunosurveillance in the tumor microenvironment of colorectal cancer is associated with low frequency tumor budding and improved outcome.
Koelzer VH; Dawson H; Andersson E; Karamitopoulou E; Masucci GV; Lugli A; Zlobec I
Transl Res; 2015 Aug; 166(2):207-17. PubMed ID: 25797890
[TBL] [Abstract][Full Text] [Related]
17. Lack of Absent in Melanoma 2 (AIM2) expression in tumor cells is closely associated with poor survival in colorectal cancer patients.
Dihlmann S; Tao S; Echterdiek F; Herpel E; Jansen L; Chang-Claude J; Brenner H; Hoffmeister M; Kloor M
Int J Cancer; 2014 Nov; 135(10):2387-96. PubMed ID: 24729378
[TBL] [Abstract][Full Text] [Related]
18. Histopathologic features of the tumor budding in adenocarcinoma of the lung: tumor budding as an index to predict the potential aggressiveness.
Yamaguchi Y; Ishii G; Kojima M; Yoh K; Otsuka H; Otaki Y; Aokage K; Yanagi S; Nagai K; Nishiwaki Y; Ochiai A
J Thorac Oncol; 2010 Sep; 5(9):1361-8. PubMed ID: 20631633
[TBL] [Abstract][Full Text] [Related]
19. High epidermal growth factor receptor expression in metastatic colorectal cancer lymph nodes may be more prognostic of poor survival than in primary tumor.
Deng Y; Kurland BF; Wang J; Bi J; Li W; Rao S; Lan P; Lin T; Lin E
Am J Clin Oncol; 2009 Jun; 32(3):245-52. PubMed ID: 19451802
[TBL] [Abstract][Full Text] [Related]
20. Systematic analysis of proteins from different signaling pathways in the tumor center and the invasive front of colorectal cancer.
Karamitopoulou E; Zlobec I; Panayiotides I; Patsouris ES; Peros G; Rallis G; Lapas C; Karakitsos P; Terracciano LM; Lugli A
Hum Pathol; 2011 Dec; 42(12):1888-96. PubMed ID: 21664646
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
